Goodwin Advised on the Acquisition of Hong Kong Women’s Imaging Group

Goodwin’s Hong Kong Private Equity team led a cross-office team in advising Tamarind Health on its acquisition of Hong Kong Women’s Imaging Limited, Hong Kong MRI Limited, Hong Kong Medical Imaging Limited, and their related affiliates (together, the “HKWI Group”) in Hong Kong. The transaction expands Tamarind Health’s presence in Hong Kong and advances its strategy of building Asia’s leading integrated oncology-focused platform.

Tamarind Health, a portfolio company of Templewater, is Asia’s leading integrated oncology-focused group, uniting renowned practices across the region to elevate care and improve patient outcomes. Headquartered in Singapore, the doctor-led platform brings together specialists across the full spectrum of oncology, from diagnostics and treatment to survivorship and well-being.

Templewater is an Asia-based alternative asset manager headquartered in Hong Kong. Templewater provides investment solutions to global institutions, family offices, and high-net-worth individuals, with a focus on two core pan-Asia strategies: mid-market private equity buyouts and energy transition venture growth. Templewater’s mission is to provide financial and human capital, operational expertise, a corporate governance framework, and integrity to build leading businesses.

The Goodwin team was led by Edwin Chan and included Ingram Cheung, Eugena Tong, Monique Chan, Tanya Choudhary, and Vivian Lee (Private Equity M&A); Steve Howard, Dora Cheung, and Christopher Ho (Debt Finance); Dulcie Daly and Matthew Rees (Tax); David Chen, Gabe Maldoff, Longfei Fang, and Lilly Weitz (Privacy & IP); and William Stern, Ce Li, and Nick Ognibene (ABC/AML).

For more information on the deal, please read the press release.